Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. more
Time Frame | PCVX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 39.17% | 0.53% | -1.09% |
1-Month Return | 50.05% | 6.67% | 6.81% |
3-Month Return | 53.86% | 7.92% | 4.49% |
6-Month Return | 52.55% | 7.19% | 7.79% |
1-Year Return | 114.02% | 18.48% | 22.93% |
3-Year Return | 321.43% | 15.12% | 22.29% |
5-Year Return | 317.4% | 73.77% | 88.01% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 1.23M | 1.41M | 1.80M | 9.20M | 10.17M | [{"date":"2019-12-31","value":12.11,"profit":true},{"date":"2020-12-31","value":13.81,"profit":true},{"date":"2021-12-31","value":17.7,"profit":true},{"date":"2022-12-31","value":90.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (1.23M) | (1.41M) | (1.80M) | (9.20M) | (10.17M) | [{"date":"2019-12-31","value":-123200000,"profit":false},{"date":"2020-12-31","value":-140500000,"profit":false},{"date":"2021-12-31","value":-180000000,"profit":false},{"date":"2022-12-31","value":-919600000,"profit":false},{"date":"2023-12-31","value":-1017100000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 53.92M | 87.10M | 102.08M | 207.33M | 382.87M | [{"date":"2019-12-31","value":14.08,"profit":true},{"date":"2020-12-31","value":22.75,"profit":true},{"date":"2021-12-31","value":26.66,"profit":true},{"date":"2022-12-31","value":54.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (54.15M) | (89.58M) | (103.67M) | (232.26M) | (393.04M) | [{"date":"2019-12-31","value":-5415300000,"profit":false},{"date":"2020-12-31","value":-8958100000,"profit":false},{"date":"2021-12-31","value":-10367000000,"profit":false},{"date":"2022-12-31","value":-23225600000,"profit":false},{"date":"2023-12-31","value":-39304100000,"profit":false}] |
Total Non-Operating Income/Expense | 4.47M | 601.00K | 3.93M | 17.13M | 53.68M | [{"date":"2019-12-31","value":8.33,"profit":true},{"date":"2020-12-31","value":1.12,"profit":true},{"date":"2021-12-31","value":7.32,"profit":true},{"date":"2022-12-31","value":31.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (50.27M) | (89.22M) | (100.08M) | (223.49M) | (402.27M) | [{"date":"2019-12-31","value":-5027400000,"profit":false},{"date":"2020-12-31","value":-8921700000,"profit":false},{"date":"2021-12-31","value":-10007700000,"profit":false},{"date":"2022-12-31","value":-22348500000,"profit":false},{"date":"2023-12-31","value":-40226600000,"profit":false}] |
Income Taxes | 3.23M | (1.40M) | 7.00K | 16.16M | - | [{"date":"2019-12-31","value":19.96,"profit":true},{"date":"2020-12-31","value":-8.65,"profit":false},{"date":"2021-12-31","value":0.04,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (53.50M) | (87.82M) | (100.08M) | (239.64M) | - | [{"date":"2019-12-31","value":-5349900000,"profit":false},{"date":"2020-12-31","value":-8781900000,"profit":false},{"date":"2021-12-31","value":-10008400000,"profit":false},{"date":"2022-12-31","value":-23964000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (50.27M) | (89.22M) | (100.08M) | (223.49M) | (402.27M) | [{"date":"2019-12-31","value":-5027400000,"profit":false},{"date":"2020-12-31","value":-8921700000,"profit":false},{"date":"2021-12-31","value":-10007700000,"profit":false},{"date":"2022-12-31","value":-22348500000,"profit":false},{"date":"2023-12-31","value":-40226600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (53.50M) | (87.82M) | (100.08M) | (239.64M) | (402.27M) | [{"date":"2019-12-31","value":-5349900000,"profit":false},{"date":"2020-12-31","value":-8781900000,"profit":false},{"date":"2021-12-31","value":-10008400000,"profit":false},{"date":"2022-12-31","value":-23964000000,"profit":false},{"date":"2023-12-31","value":-40226600000,"profit":false}] |
EPS (Diluted) | (1.08) | (2.83) | (1.93) | (3.43) | (4.13) | [{"date":"2019-12-31","value":-108,"profit":false},{"date":"2020-12-31","value":-283,"profit":false},{"date":"2021-12-31","value":-193,"profit":false},{"date":"2022-12-31","value":-343,"profit":false},{"date":"2023-12-31","value":-413,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PCVX | |
---|---|
Cash Ratio | 17.53 |
Current Ratio | 17.88 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PCVX | |
---|---|
ROA (LTM) | -20.10% |
ROE (LTM) | -29.08% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PCVX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PCVX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 4.54 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Vaxcyte Inc (PCVX) share price today is $109.15
Yes, Indians can buy shares of Vaxcyte Inc (PCVX) on Vested. To buy Vaxcyte Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PCVX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Vaxcyte Inc (PCVX) via the Vested app. You can start investing in Vaxcyte Inc (PCVX) with a minimum investment of $1.
You can invest in shares of Vaxcyte Inc (PCVX) via Vested in three simple steps:
The 52-week high price of Vaxcyte Inc (PCVX) is $119.27. The 52-week low price of Vaxcyte Inc (PCVX) is $44.2.
The price-to-earnings (P/E) ratio of Vaxcyte Inc (PCVX) is
The price-to-book (P/B) ratio of Vaxcyte Inc (PCVX) is 4.54
The dividend yield of Vaxcyte Inc (PCVX) is 0.00%
The market capitalization of Vaxcyte Inc (PCVX) is $12.29B
The stock symbol (or ticker) of Vaxcyte Inc is PCVX